ArticleJournal of thoracic disease2025
Global trends in research on radiofrequency ablation for lung cancer: a bibliometric and visualization analysis (2008-2024).
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For early-stage non-small cell lung cancer, surgical resection is the preferred treatment. However, for elderly patients, those with comorbidities, or those with poor lung function, it may be difficult for them to tolerate the surgery. Radiofrequency ablation (RFA) precisely damages the tumor through thermal energy, is minimally invasive, has a quick recovery, and maximally preserves lung function. It has become an important option for patients who are not suitable for surgery. This study aimed to explore the research hotspots and development trends in the field of RFA of lung cancer through bibliometric analysis. Methods: Web of Science Core Collection (WoSCC) was used to search for articles on RFA for lung cancer. CiteSpace and VOSviewer software were used to analyze the publication trend, country, institution, author, journal, keywords, etc. Results: A total of 1,367 articles were retrieved. China ranked first in publication volume (n=413), but its institutional average citation and H-index were lower than those of European and American institutions. Harvard University and UNICANCER showed higher academic influence. Conclusions: The research on RFA for lung cancer has formed a complete innovation chain of "technology evolution, safety verification, clinical practice, prognosis optimization", which is deepening from single ablation technology to multimodal combined treatment and molecular mechanism research. Interdisciplinary cooperation and the integration of emerging omics analysis promote the transformation of the field to evidence-based medicine. In the future, it is necessary to strengthen transnational cooperation network and focus on real-world long-term efficacy verification and drug resistance mechanism analysis, so as to accelerate the strategic upgrading of RFA from a local ablation technology to an individualized, interdisciplinary integrated treatment paradigm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.